ArticleNeurology2020
Association of specific biotypes in patients with Parkinson disease and disease progression.
Article in Neurology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 38 citations in OpenAlex.
- Spatiotemporal Progression Patterns of Striatal Dopamine Depletion and Cerebral Hypoperfusion in Parkinson's Disease.Movement disorders : official journal of the Movement Disorder Society · 2026Article
- Identifing two distinct cortical progression subtypes of Parkinson's disease through multimodal neuroimaging.European journal of nuclear medicine and molecular imaging · 2026Article
- A Canonical Neural Map and Its Deviations Shape Parkinson's Disease Phenotypes.Research square · 2026Article
- Data-driven subtyping of Parkinson's disease using MRI: current insights, challenges, and future directions.Frontiers in aging neuroscience · 2026Review
- Diagnostic utility of biomarkers in progressive supranuclear palsy: toward a biotyping framework.Journal of neurology · 2025Review
- Brain-clinical biotyping in patients with idiopathic REM sleep behavior disorder.NPJ Parkinson's disease · 2025Article
- Atlas of Proteomic signatures of brain structure and its links to brain disorders.Nature communications · 2025Article
- Moving toward precision and personalized treatment strategies in psychiatry.The international journal of neuropsychopharmacology · 2025Review
- Analysis of Two Neuroanatomical Subtypes of Parkinson's Disease and Their Motor Progression Based on Semi-Supervised Machine Learning.CNS neuroscience & therapeutics · 2025Article
- MRI subtypes in Parkinson's disease across diverse populations and clustering approaches.NPJ Parkinson's disease · 2024Article
- Pain in Parkinson's disease: a neuroanatomy-based approach.Brain communications · 2024Review
- Identification of Parkinson's disease subtypes with distinct brain atrophy progression and its association with clinical progression.Psychoradiology · 2024Article
- Two distinct trajectories of clinical and neurodegeneration events in Parkinson's disease.NPJ Parkinson's disease · 2023Article
- Behavioral and biologic characteristics of cancer-related cognitive impairment biotypes.Brain imaging and behavior · 2023Article
- Artificial intelligence-based clustering and characterization of Parkinson's disease trajectories.Scientific reports · 2023Article
- Retinal electrophysiology in central nervous system disorders. A review of human and mouse studies.Frontiers in neuroscience · 2023Review
- Neuroimaging based biotypes for precision diagnosis and prognosis in cancer-related cognitive impairment.Frontiers in medicine · 2023Review
- The longitudinal progression of autonomic dysfunction in Parkinson's disease: A 7-year study.Frontiers in neurology · 2023Article
- Magnetic Resonance Imaging Studies of Neurodegenerative Disease: From Methods to Translational Research.Neuroscience bulletin · 2023Review
- Deep phenotyping for precision medicine in Parkinson's disease.Disease models & mechanisms · 2022Article
Corrections and comments
- Commented on by
Authors and funding
12 authors at 1 institution in 3 countries.
Funding
Abstract
objectiveTo identify biotypes in patients with newly diagnosed Parkinson disease (PD) and to test whether these biotypes could explain interindividual differences in longitudinal progression.
methodsIn this longitudinal analysis, we use a data-driven approach clustering PD patients from the Parkinson's Progression Markers Initiative (n = 314, age 61.0 ± 9.5, years 34.1% female, 5 years of follow-up). Voxel-level neuroanatomic features were estimated with deformation-based morphometry (DBM) of T1-weighted MRI. Voxels with deformation values that were significantly correlated (
resultsTwo neuroanatomic biotypes were identified: biotype 1 (n = 114) with subcortical brain volumes smaller than heathy controls and biotype 2 (n = 200) with subcortical brain volumes larger than heathy controls. Biotype 1 had more severe motor impairment, autonomic dysfunction, and much worse REM sleep behavior disorder than biotype 2 at baseline. Although disease durations at the initial visit and follow-up were similar between biotypes, patients with PD with smaller subcortical brain volume had poorer prognosis, with more rapid decline in several clinical domains and in dopamine functional neuroimaging over an average of 5 years.
conclusionRobust neuroanatomic biotypes exist in PD with distinct clinical and neuroanatomic patterns. These biotypes can be detected at diagnosis and predict the course of longitudinal progression, which should benefit trial design and evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.